- Home
- PSBD vs MXCT Comparison
PSBD vs MXCT Comparison
Compare PSBD & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- MXCT
- Stock Information
- Founded
- PSBD 2009
- MXCT 1999
- Country
- PSBD United States
- MXCT United States
- Employees
- PSBD N/A
- MXCT N/A
- Industry
- PSBD
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PSBD
- MXCT Health Care
- Exchange
- PSBD Nasdaq
- MXCT Nasdaq
- Market Cap
- PSBD 507.0M
- MXCT 534.8M
- IPO Year
- PSBD 2024
- MXCT 2021
- Fundamental
- Price
- PSBD $15.30
- MXCT $3.85
- Analyst Decision
- PSBD Buy
- MXCT Strong Buy
- Analyst Count
- PSBD 7
- MXCT 2
- Target Price
- PSBD $16.93
- MXCT $9.50
- AVG Volume (30 Days)
- PSBD 19.0K
- MXCT 448.2K
- Earning Date
- PSBD 03-03-2025
- MXCT 03-11-2025
- Dividend Yield
- PSBD 12.44%
- MXCT N/A
- EPS Growth
- PSBD N/A
- MXCT N/A
- EPS
- PSBD N/A
- MXCT N/A
- Revenue
- PSBD N/A
- MXCT $45,599,000.00
- Revenue This Year
- PSBD N/A
- MXCT N/A
- Revenue Next Year
- PSBD N/A
- MXCT $20.23
- P/E Ratio
- PSBD N/A
- MXCT N/A
- Revenue Growth
- PSBD N/A
- MXCT 19.85
- 52 Week Low
- PSBD $15.12
- MXCT $3.17
- 52 Week High
- PSBD $17.09
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- PSBD 41.31
- MXCT 35.05
- Support Level
- PSBD $15.30
- MXCT $4.06
- Resistance Level
- PSBD $15.74
- MXCT $4.32
- Average True Range (ATR)
- PSBD 0.35
- MXCT 0.20
- MACD
- PSBD -0.04
- MXCT -0.07
- Stochastic Oscillator
- PSBD 2.60
- MXCT 4.65
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.